Trial Profile
A Randomized Phase III Trial of Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab Versus Platinum Chemotherapy Plus Paclitaxel and Bevacizumab in Metastatic (Stage IVB), Persistent, or Recurrent Carcinoma of the Cervix
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab; Carboplatin; Cisplatin; Paclitaxel
- Indications Adenocarcinoma; Adenosquamous carcinoma; Cervical cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms BEATcc
- 04 Mar 2024 Planned End Date changed from 1 Mar 2024 to 1 Nov 2024.
- 04 Mar 2024 Planned primary completion date changed from 1 Mar 2024 to 1 Nov 2024.
- 01 Dec 2023 Primary endpoint has been met. (Progression free survival (PFS)) , according to Results published in The Lancet.